The Alzheimer's Disease Diagnosis and Plasma Phospho‐Tau217 (ADAPT) study stage 1: Validating clinical cut‐points against CSF and amyloid PET
Lumipulse plasma p-tau217, now available in our United Kingdom Accreditation Service-accredited clinical National Health Service laboratory, will be used in a randomized trial of p-tau217 result disclosure in memory services.
Authors
- P O Wilson
- Melanie Hart (ORCID: https://orcid.org/0000-0002-7396-1916)
- Ryan W. S. Wee (ORCID: https://orcid.org/0000-0003-0273-5521)
- Katharine Wiltshire
- Katie Tucker (ORCID: https://orcid.org/0009-0009-0349-3107)
- Laura Rizzo
- Irene Gorostiaga Belio
- Daniel P. Gale
- Paresh Malhotra
- Jonathan M. Schott
- Michael C. B. David
- Omid Sadeghi‐Alavijeh
- Michael P. Lunn
- Nick C. Fox
- Henrik Zetterberg
- Amanda J. Heslegrave
Institutions
- University College London Hospitals NHS Foundation Trust (GB)
- University of Wisconsin–Madison (US)
- The Francis Crick Institute (GB)
- Sahlgrenska University Hospital (SE)
- King's College Hospital NHS Foundation Trust (GB)
- Institute for Neurodegenerative Disorders (US)
- UK Dementia Research Institute (GB)
- MRC Prion Unit (GB)
- National Hospital for Neurology and Neurosurgery (GB)
- University College London (GB)
- Imperial College London (GB)
- University of Gothenburg (SE)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1002/alz.71147
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Polycystic Kidney Disease Charity
- Alzheimer's Society
- National Institute for Health and Care Research
- Imperial College London
- University College London
- University College London Hospitals NHS Foundation Trust
- UK Dementia Research Institute